Trial Outcomes & Findings for Hernia Repair in Multiply Morbid Patients (NCT NCT00930787)

NCT ID: NCT00930787

Last Updated: 2013-11-20

Results Overview

Recruitment status

TERMINATED

Study phase

PHASE4

Target enrollment

23 participants

Primary outcome timeframe

Postoperative Day 30

Results posted on

2013-11-20

Participant Flow

23 subjects recruited from 9 US sites between August 2009 and May 2010.

Participant milestones

Participant milestones
Measure
Strattice Reconstructive Tissue Matrix
Use of Strattice Reconstructive Tissue Matrix to support hernia repair
Proceed Surgical Mesh
Use of Proceed Surgical Mesh to support hernia repair
Overall Study
STARTED
14
9
Overall Study
COMPLETED
14
9
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Hernia Repair in Multiply Morbid Patients

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Strattice Reconstructive Tissue Matrix
n=14 Participants
Use of Strattice Reconstructive Tissue Matrix to support hernia repair
Proceed Surgical Mesh
n=9 Participants
Use of Proceed Surgical Mesh to support hernia repair
Total
n=23 Participants
Total of all reporting groups
Age Continuous
58.2 years
STANDARD_DEVIATION 11.47 • n=5 Participants
52.7 years
STANDARD_DEVIATION 13.54 • n=7 Participants
56 years
STANDARD_DEVIATION 12 • n=5 Participants
Sex: Female, Male
Female
11 Participants
n=5 Participants
3 Participants
n=7 Participants
14 Participants
n=5 Participants
Sex: Female, Male
Male
3 Participants
n=5 Participants
6 Participants
n=7 Participants
9 Participants
n=5 Participants

PRIMARY outcome

Timeframe: Postoperative Day 30

Population: Study was terminated early and no analyses were conducted.

Outcome measures

Outcome data not reported

Adverse Events

Strattice Reconstructive Tissue Matrix

Serious events: 0 serious events
Other events: 14 other events
Deaths: 0 deaths

Proceed Surgical Mesh

Serious events: 1 serious events
Other events: 9 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Strattice Reconstructive Tissue Matrix
n=14 participants at risk
Use of Strattice Reconstructive Tissue Matrix to support hernia repair
Proceed Surgical Mesh
n=9 participants at risk
Use of Proceed Surgical Mesh to support hernia repair
Infections and infestations
Wound Infection
0.00%
0/14
11.1%
1/9 • Number of events 1

Other adverse events

Other adverse events
Measure
Strattice Reconstructive Tissue Matrix
n=14 participants at risk
Use of Strattice Reconstructive Tissue Matrix to support hernia repair
Proceed Surgical Mesh
n=9 participants at risk
Use of Proceed Surgical Mesh to support hernia repair
Surgical and medical procedures
Incisional drainage
0.00%
0/14
11.1%
1/9 • Number of events 1
Injury, poisoning and procedural complications
Wound dehiscence
28.6%
4/14 • Number of events 5
11.1%
1/9 • Number of events 5
Cardiac disorders
Atrial fibrillation
0.00%
0/14
22.2%
2/9 • Number of events 2
Gastrointestinal disorders
Abdominal hernia
0.00%
0/14
11.1%
1/9 • Number of events 1
Gastrointestinal disorders
Localised intraabdominal fluid
0.00%
0/14
11.1%
1/9 • Number of events 1
Injury, poisoning and procedural complications
Seroma
21.4%
3/14 • Number of events 5
22.2%
2/9 • Number of events 5
Investigations
International normalised ratio increased
0.00%
0/14
11.1%
1/9 • Number of events 1
Investigations
Urine output decreased
28.6%
4/14 • Number of events 4
0.00%
0/9
Respiratory, thoracic and mediastinal disorders
Respiratory distress
0.00%
0/14
11.1%
1/9 • Number of events 1
Vascular disorders
Hypertension
0.00%
0/14
11.1%
1/9 • Number of events 1
Gastrointestinal disorders
Nausea
35.7%
5/14 • Number of events 6
11.1%
1/9 • Number of events 6
Gastrointestinal disorders
Rectal haemorrhage
0.00%
0/14
11.1%
1/9 • Number of events 1
Gastrointestinal disorders
Vomiting
14.3%
2/14 • Number of events 3
11.1%
1/9 • Number of events 3
General disorders
Pyrexia
35.7%
5/14 • Number of events 5
0.00%
0/9
Infections and infestations
Incision site infection
0.00%
0/14
11.1%
1/9 • Number of events 1

Additional Information

Dr Michael Franz

LifeCell

Phone: 908094701100

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place